JBIO
Jade Biosciences, Inc.
$13.73
+0.26
(+1.94%)
Mkt Cap
856.66M
Volume
278,749
52W Range
8.36-28
Sector
Healthcare
Beta
1.45
EPS (TTM)
-3.12 USD
P/E Ratio
-3.80
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (127.41M) | (69.63M) | (75.52M) | (51.51M) | (22.96M) | (9.61M) |
| EPS | -4.06 | -85.26 | -100.38 | -73.67 | -32.96 | -14.00 |
| Free Cash Flow | (94.89M) | (71.20M) | (56.92M) | (39.32M) | (27.58M) | (7.86M) |
| FCF / Share | -3.03 | -87.18 | -75.66 | -56.23 | -39.54 | -11.27 |
| Operating CF | (94.69M) | (71.20M) | (56.78M) | (39.12M) | (27.40M) | (7.86M) |
| Total Assets | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M | 4.71M |
| Total Debt | 724,000 | 417,000 | 675,000 | 1.09M | 574,000 | 0 |
| Cash & Equiv | 88.44M | 33.75M | 23.49M | 22.40M | 54.20M | 4.57M |
| Book Value | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M | 2.94M |
| Return on Equity | -0.38 | -0.91 | -0.69 | -0.41 | -0.13 | -3.27 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (40.37M) | (31.93M) | (25.18M) | (32.13M) | (2.52M) | (5.43M) | (16.28M) | (24.77M) | (23.19M) | (20.41M) | (19.56M) |
| EPS | -0.70 | -0.65 | -0.64 | -1.13 | -3.04 | -6.56 | -5.16 | -30.15 | -29.20 | -25.80 | -24.77 |
| Free Cash Flow | (24.08M) | (33.65M) | (22.18M) | (20.16M) | N/A | (15.81M) | (6.80M) | (20.43M) | (23.67M) | (14.86M) | (15.64M) |
| FCF / Share | -0.42 | -0.68 | -0.56 | -0.71 | N/A | -19.09 | -2.16 | -24.87 | -29.81 | -18.78 | -19.81 |
| Operating CF | (24.08M) | (33.65M) | (22.12M) | (20.16M) | N/A | (15.81M) | (6.80M) | (20.43M) | (23.67M) | (14.80M) | (15.61M) |
| Total Assets | 319.43M | 349.78M | 202.45M | 223.97M | 77.53M | 80.33M | 90.96M | 111.69M | 106.82M | 127.42M | 140.88M |
| Total Debt | 679,000 | 724,000 | 747,000 | 792,000 | 312,000 | 417,000 | 540,000 | 681,000 | 774,000 | 675,000 | 809,000 |
| Cash & Equiv | 55.09M | 88.44M | 50.11M | 220.94M | 44.22M | 33.75M | 31.11M | 31.07M | 9.12M | 23.49M | 32.18M |
| Book Value | 296.46M | 332.52M | 179.35M | 201.56M | 75.05M | 76.43M | 80.49M | 94.40M | 90.90M | 109.46M | 125.72M |
| Return on Equity | -0.14 | -0.10 | -0.14 | -0.16 | -0.03 | -0.07 | -0.20 | -0.26 | -0.26 | -0.19 | -0.16 |
JBIO News
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences: Duration Is The Real Product
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jade Biosciences Announces Pricing of Public Offering of Common Stock